Catalent Announces Integrated Service for OSD

October 1, 2020

The OneXpress solution is designed to accelerate oral dosage drug development and manufacturing.

Catalent announced the launch of OneXpress, a service designed to accelerate the transition of new oral solid dosage form drugs from early-phase development to commercial manufacturing. The service will offer integrated development, scale up, and manufacturing and will use the company’s phase-appropriate scale, technologies, oral dose form network, and expertise, the company reported in an Oct. 1, 2020 press statement.

The services will be provided by the company’s early-phase drug development centers in Nottingham, UK, Somerset, NJ, and San Diego, CA, as well as the company’s oral solid commercial manufacturing facilities.

“The oral drug development path is lengthy and complex, so to maximize speed and flexibility and reduce costs, innovators need to select development partners with the expertise and capabilities that are best suited for each stage in their development cycle,” said Jeremie Trochu, vice-president, oral and specialty delivery at Catalent, in the statement. “Our teams have collaborated across sites to harmonize equipment, materials, and protocols, to ensure accelerated and seamless scale up from first-in-human trials to commercial launch. We successfully transferred over a dozen OneXpress projects in the last year alone.”

Source: Catalent